We develop cancer medicines with life-changing potential for patients including ovarian cancer, endometrial cancer and multiple myeloma.
We have developed a new monoclonal antibody treatment for COVID-19. Monoclonal antibodies work in a similar way to the human immune system and can help people who do not have a strong natural immune response to a virus.
We delivered three major product approvals in 2021 for endometrial cancer, COVID-19 and HIV.
Our vaccines portfolio is the broadest in the industry, helping protect people from meningitis, shingles, flu, polio, measles and many more.
We have three marketed cancer therapies, with a further nine assets in development.
We're focusing on antimicrobial resistance and drug-resistant infections with 28 R&D projects targeting priority pathogens including those deemed ‘critical’ and ‘urgent’ by the World Health Organization.
Two million of our vaccines are administered every day, and 40% of the world’s children receive a GSK vaccine each year.
Since 2017, we’ve delivered 13 major approvals and more than doubled the number of potential new vaccines and medicines we have in Phase 3 and registration, to 23.
Our ground-breaking malaria vaccine is the first and only vaccine shown in long-term clinical trials to reduce malaria in children.